Top Health Care Stocks
Health care stocks were mostly lower, with the NYSE Health Care
Sector Index retreating about 0.7% and shares of health care
companies in the S&P 500 down about 0.6% as a group.
In company news, Advaxis Inc. (
) was higher Monday after federal regulators cleared the biotech
company to begin Phase I/II testing early next year of its ADXS-HPV
anti-cancer therapy either alone or in combination with
) MEDI4736 drug candidate.
ADXS shares were up 15% at $4.35 apiece, just 4 cents off their
session high. The stock has traded within a 52-week range of $2.46
to $5.99 a share, declining almost 12% over the past year prior to
Approval of ADXS' Investigational New Drug application by the
U.S. Food and Drug Administration allows the company to proceed
with a trial to evaluate ADXS-HPV as a prospective treatment for
advanced, recurrent or refractory human papillomavirus-associated
cervical cancer and HPV-associated head and neck cancer.
The company and AZN, through its Medimmune unit, in July
announced their plans to collaborate on clinical testing of their
respective lead cancer drugs.
During the Phase I part of the trial, researchers will conduct a
dose-confirmation study of ADXS-HPV as a monotherapy and together
with MEDI4736, a human monoclonal antibody that works to counter
immune-evading tactics by tumors. The Phase II study will assess
the safety and measure the clinical activity of the combination and
AZN shares were falling this afternoon, down almost 3% at $69.89
In other sector news,
(+) OPK, (+8.9%) Signs global commercialization agreement with
) for its long-acting hGH-CTP human growth hormone. Receives $295
mln upfront payment and is eligible for up to $275 mln in future
(-) SPHS, (-79.8%) Independent Data Monitoring Committee
determines PRX302 drug candidate did not achieve a predefined
efficacy threshold as a potential treatment for lower urinary tract
symptoms of Benign prostatic hyperplasia.